Wyeth's reports strong Phase III bazedoxifene data

At the American Society for Bone and Mineral Research Annual Meeting, Wyeth presented strong Phase III data for its osteoporosis drug. Bazedoxifene 20 mg and 40 mg significantly reduced the risk of new vertebral fractures by 42 percent and 37 percent, respectively, in a three-year study. Bazedoxifene has already been submitted to the FDA and is awaiting final approval. Earlier this year, Wyeth received an FDA approvable letter for bazedoxifene for the prevention of postmenopausal osteoporosis. In July 2007, Wyeth submitted a separate new drug application to the FDA for bazedoxifene for the treatment of postmenopausal osteoporosis. This new data comes as much-needed good news for Wyeth, which has struggled with its drug development programs as of late.

- see Wyeth's release for more on bazedoxifene

Related Articles:
Wyeth stumbles badly trying to develop new drugs. Report
Wyeth stock down after several setbacks. Report
Novartis drug cuts hip-fracture deaths. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.